Emerging antiobesity drugs

Expert Opinion on Emerging Drugs

Volumn 8, Issue 1, 2003, Pages 217-237

  Spanswick, David ^a,b   Lee, Kevin ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b NEUROSOLUTIONS LTD   (United Kingdom)

Author keywords

5 HT re uptake inhibitors; Antiobesity drugs; CNTF; Ghrelin; Growth hormone secretagogues; Hypothalamus; Leptin; Lipase; Melanocortins; Neuropetide Y; Orexins; PYY3 36; Uncoupling proteins

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTIOBESITY AGENT; ATL 962; BENZPHETAMINE; BVT 933; CLOMIPRAMINE; ENTEROSTATIN; EPHEDRINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; GHRELIN; GI 181771; GL 181771; LEPTIN; LY 377604; MANIFAXINE; MAZINDOL; NEUROPEPTIDE Y; P 57; PHENTERMINE; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT LEPTIN; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIMELDINE;

ADIPOCYTE; BODY MASS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DRUG INDICATION; DRUG MECHANISM; DRUG RELEASE; DRUG STRUCTURE; DRUG TARGETING; ECONOMIC EVALUATION; ENDOCRINE DISEASE; ENERGY BALANCE; ENERGY EXPENDITURE; EPIDEMIC; ETHNOLOGY; FOOD INTAKE; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEADACHE; HEALTH CARE COST; HOMEOSTASIS; HORMONE RELEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; LIFESTYLE; LIPID DIET; NAUSEA; NEUROTOXICITY; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; RESTLESSNESS; REVIEW; SIDE EFFECT; STOMACH BYPASS; SYMPATHETIC INNERVATION; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; HUMANS; OBESITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037981251     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.1.217     Document Type: Review

References (158)

1. KUCZMARSKI RJ, FLEGAL KM, CAMPBELL SM, JOHNSON CL: Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA (1994) 272(3):205-211.
2. WOLF AM, COLDITZ GA: Current estimates of the economic cost of obesity in the United States. Obes. Res. (1998) 6(2):97-106. Paper emphasising the financial burden this epidemic poses.
3. SCHWARTZ MW, BASKIN DG, KAIYALA KJ, WOODS SC: Model for the regulation of energy balance and adiposity by the central nervous system. Am. J. Clin. Nutr. (1999) 69(4):584-596. An excellent review of the central integration of neural and hormonal signallig and forwarding a unifying hypothesis on how the multitude of orexigenic and anorexigenic signals are integrated at the level of the CNS.
4. WOODS SC, SCHWARTZ MW, BASKIN DG, SEELEY RJ: Food intake and the regulation of body weight. Annu. Rev. Psychol. (2000) 51:255-277. An excellent review of the central integration of neural and hormonal signalling.
5. KENNEDY GS: The role of fat depot fat in the hypothalamic control of food intake in the rat. Proc. R. Soc. Lond. B. Biol. Sci. (1953) 140:578-592.
6. AHIMA RS, FLIER JS: Leptin. Annu. Rev. Physiol (2000) 62:413-437. Reviews all aspects of the hormone leptin.
7. KALRA SP, DUBE MG, PU S, XU B, HORVATH TL, KALRA PS: Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. (1999) 20(1):68-100.
8. SAWCHENKO PE: Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J. Comp. Neurol. (1998) 402(4):435-441. Excellent review of the central neural pathways involved in regulating energy balance.
9. BRUNING JC, GAUTAM D, BURKS DJ et al.: Role of brain insulin receptor in control of body weight and reproduction. Science (2000) 289:2122-2125.
10. SCHWARTZ MW, FIGLEWICZ DP, BASKIN DG, WOODS SC, PORTE D JR: Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. (1992) 13(3):387-414.
11. SCHWARTZ MW, SIPOLS AJ, MARKS JL et al.: Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology (1992) 130(6):3608-3616.
12. SCHWARTZ MW, MARKS JL, SIPOLS AJ et al.: Central insulin administration reduces neuropeptide Y mRNA expression in the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker rats. Endocrinology (1991) 128(5):2645-2647.
13. KOJIMA M, HOSODA H, DATE Y, NAKAZATO M, MATSUO H, KANGAWA K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402:656-660.
14. DATE Y, NAKAZATO M, MURAKAMI N, KOJIMA M, KANGAWA K, MATSUKURA S: Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem. Biophys. Res. Commun. (2001) 280(3):904-907.
15. KAMEGAI J, TAMURA H, SHIMIZU T, ISHII S, SUGIHARA H, WAKABAYASHI I: Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes (2001) 50(11):2438-2443.
16. KAMEGAI J, TAMURA H, SHIMIZU T, ISHII S, SUGIHARA H, WAKABAYASHI I: Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology (2000) 141(12):4797-4800.
17. LAWRENCE CB, SNAPE AC, BAUDOIN FM, LUCKMAN SM: Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology (2002) 143(1):155-162.
18. KEIRE DA, MANNON P, KOBAYASHI M, WALSH JH, SOLOMON TE, REEVE JR JR: Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) 279(1):G126-G131.
19. ADRIAN TE, FERRI GL, BACARESE-HAMILTON AJ, FUESSL HS, POLAK JM, BLOOM SR: Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology (1985) 89(5):1070-1077.
20. GRANDT D, SCHIMICZEK M, BEGLINGER C et al.: Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul. Pept. (1994) 51(2):151-159.
21. BATTERHAM RL, COWLEY MA, SMALL CJ et al.: Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 418:650-654.
22. BASKIN DG, SEELEY RJ, KUIJPER JL et al.: Increased expression of mRNA for the long form of the leptin receptor in the hypothalamus is associated with leptin hypersensitivity and fasting. Diabetes (1998) 47(4):538-543.
23. COWLEY MA, SMART JL, RUBINSTEIN M et al.: Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature (2001) 411:480-484.
24. HAYNES WG, MORGAN DA, DJALALI A, SIVITZ WI, MARK AL: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension (1999) 33:542-547.
25. HAYNES WG, MORGAN DA, WALSH SA, MARK AL, SMTZ WI: Receptor-mediated regional sympathetic nerve activation by leptin. J. Clin. Invest. (1997) 100(2):270-278.
26. SPANSWICK D, SMITH MA, MIRSHAMSI S, ROUTH VH, ASHFORD ML: Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat. Neurosci. (2000) 3(8):757-758.
27. SPANSWICK D, SMITH MA, GROPPI VE, LOGAN SD, ASHFORD ML: Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels. Nature (1997) 390:521-525.
28. TANNENBAUM GS, BOWERS CY: Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin. Endocrine (2001) 14(1):21-27.
29. HAKANSSON ML, BROWN H, GHILARDI N, SKODA RC, MEISTER B: Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. J. Neurosci. (1998) 18(1):559-572.
30. MERCER JG, HOGGARD N, WILLIAMS LM et al.: Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus. J. Neuroendocrinol. (1996) 8(10):733-735.
31. CHEUNG CC, CLIFTON DK, STEINER RA: Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology (1997) 138(10):4489-4492.
32. HAHN TM, BREININGER JF, BASKIN DG, SCHWARTZ MW: Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat. Neurosci. (1998) 1(4):271-272.
33. OLLMANN MM, WILSON BD, YANG YK et al.: Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science (1997) 278:135-138.
34. MURPHY B, NUNES CN, RONAN JJ et al.: Melanocortin mediated inhibition of feeding behavior in rats. Neuropeptides (1998) 32(6):491-497.
35. THIELE TE, VAN DIJK G, YAGALOFF KA et al.: Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion. Am. J. Physiol. (1998) 274(1 Pt 2):R248-R254.
36. TSUJII S, BRAY GA: Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res. Bull. (1989) 23(3):165-169.
37. ROSSI M, KIM MS, MORGAN DG et al.: A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology (1998) 139(10):4428-4431.
38. KRISTENSEN P, JUDGE ME, THIM L et al.: Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature (1998) 393:72-76.
39. SCHWARTZ MW, SEELEY RJ, WOODS SC et al.: Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes (1997) 46(12):2119-2123.
40. SCHWARTZ MW, SEELEY RJ, CAMPFIELD LA, BURN P, BASKIN DG: Identification of targets of leptin action in rat hypothalamus. J. Clin Invest. (1996) 98(5):1101-1106.
41. ELLAS CF, LEE CE, KELLY JF et al.: Characterization of CART neurons in the rat and human hypothalamus. J. Comp. Neurol. (2001) 432(1):1-19.
42. ELLAS CF, LEE C, KELLY J et al.: Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron (1998) 21(6):1375-1385.
43. LU S, GUAN JL, WANG QP et al.: Immunocytochemical observation of ghrelin-containing neurons in the rat arcuate nucleus. Neurosci. Lett. (2002) 321(3):157-160.
44. REYES TM, LEWIS K, PERRIN MH et al.: Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. USA (2001) 98(5):2843-2848.
45. HOWARD AD, WANG R, PONG SS et al.: Identification of receptors for neuromedin U and its role in feeding. Nature (2000) 406:70-74.
46. BAKER RA, HERKENHAM M: Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. J. Comp. Neurol. (1995) 358(4):518-530.
47. CONE RD: The central melanocortin system and energy homeostasis. Trends Endocrinol. Metab. (1999) 10(6):211-216.
48. SAWCHENKO PE, SWANSON LW: The organization of noradrenergic pathways from the brainstem to the paraventricular and supraoptic nuclei in the rat. Brain Res. (1982) 257(3):275-325.
49. BROBERGER C, DE LECEA L, SUTCLIFFE JG, HOKFELT T: Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. J. Comp. Neurol. (1998) 402(4):460-474.
50. ELIAS CF, SAPER CB, MARATOS-FLIER E et al.: Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J. Comp. Neurol (1998) 402(4):442-459.
51. KOYLU EO, COUCEYRO PR, LAMBERT PD, KUHAR MJ: Cocaine-and amphetamine-regulated transcript peptide immunohistochemical localization in the rat brain. J. Comp. Neurol. (1998) 391(1):115-132.
52. KOYLU EO, COUCEYRO PR, LAMBERT PD, LING NC, DESOUZA EB, KUHAR MJ: Immunohistochemical localization of novel CART peptides in rat hypothalamus, pituitary and adrenal gland. J. Neuroendocrinol. (1997) 9(11):823-833.
53. VAN DEN POL AN, GAO XB, OBRIETAN K, KILDUFF TS, BELOUSOV AB: Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J. Neurosci. (1998) 18(19):7962-7971.
54. MAYER J: Regulation of energy intake and bodyweight: the glucostatic theory and lipostatic hypothesis. Ann. NY Acad. Sci. (1955) 63:15-43.
55. NISWENDER KD, MORTON GJ, STEARNS WH, RHODES CJ, MYERS MGJ, SCHWARTZ MW: Key enzyme in leptin induced anorexia. Nature (2001) 413:795-796.
56. GRILL HJ, SCHWARTZ MW, KAPLAN JM, FOXHALL JS, BREININGER J, BASKIN DG: Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake. Endocrinology (2002) 143:239-246. Paper describing evidence of a key role for brainstem nuclei, in addition to the hypothalamus, as a target for leptin action and in controlling food intake.
57. HALAAS JL, GAJIWALA KS, MAFFEI M et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science (1995) 269:543-546.
58. PELLEYMOUNTER MA, CULLEN MJ, BAKER MB et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1995) 269:540-543.
59. SCHWARTZ MW, PESKIND E, RASKIND M, BOYKO EJ, PORTE D JR: Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. (1996) 2(5):589-593.
60. HALAAS JL, BOOZER C, BLAIR-WEST J, FIDAHUSEIN N, DENTON DA, FRIEDMAN JM: Physiological response to long-term peripheral and central leptin infilsion in lean and obese mice. Proc. Natl. Acad. Sci. USA (1997) 94:8878-8883.
61. IGEL M, BECKER W, HERBERG L, JOOST HG: Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology (1997) 138(10):4234-4239.
62. BANKS WA, KASTIN AJ, HUANG W, JASPAN JB, MANESS LM: Leptin enters the brain by a saturable system independent of insulin. Peptides (1996) 17(2):305-311.
63. DALLONGEVILLE J, FRUCHART JC, AUWERX J: Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators. J. Med. Chem. (1998) 41(27):5337-5352. Review considering strategies for pharmacological targeting of leptin-dependent signalling mechanisms.
64. VAN HEEK M, COMPTON DS, FRANCE CF et al.: Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest. (1997) 99(3):385-390.
65. KALRA SP, DUBE MG, SAHU A, PHELPS CP, KALRA PS: Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl. Acad. Sci. USA (1991) 88(23):10931-10935.
66. SALIN P, KERKERIAN L, NIEOULLON A: Expression of neuropeptide Y immunoreactivity in the rat nucleus accumbens is under the influence of the dopaminergic mesencephalic pathway. Exp. Brain Res. (1990) 81(2):363-371.
67. CLARK JT, KALRA PS, CROWLEY WR, KALRA SP: Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology (1984) 115(1):427-429.
68. STANLEY BG, KYRKOULI SE, LAMPERT S, LEIBOWITZ SF: Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides (1986) 7(6):1189-1192.
69. BILLINGTON CJ, BRIGGS JE, HARKER S, GRACE M, LEVINE AS: Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am. J. Physiol. (1994) 266(6 Pt 2):R1765-R1770.
70. STEPHENS TW, BASINSKI M, BRISTOW PK et al.: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature (1995) 377:530-532.
71. LEVIN BE: Arcuate NPY neurons and energy homeostasis in diet-induced obese and resistant rats. Am. J. Physiol. (1999) 276(2 Pt 2):R382-R387.
72. DUMONT Y, JACQUES D, BOUCHARD P, QUIRION R: Species differences in the expression and distribution of the neuropeptide YY1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. (1998) 402:372-384.
73. MCKEE KK, TAN CP, PALYHA OC et al.: Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics (1997) 46(3):426-434.
74. HOWARD AD, FEIGHNER SD, CULLY DF et al.: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996) 273:974-977.
75. GUAN XM, YU H, PALYHA OC et al.: Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res. Mol. Brain Res. (1997) 48(1):23-29.
76. BAILEY AR, VON ENGLEHARDT N, LENG G, SMITH RG, DICKSON SL: Growth hormone secretagogue activation of the arcuate nucleus and brainstem occurs via a non-noradrenergic pathway. J. Neuroendocrinol. (2000) 12(3):191-197.
77. WREN AM, SMALL CJ, ABBOTR CR et al.: Ghrelin causes hyperphagia and obesity in rats. Diabetes (2001) 50(11):2540-2547.
78. NAKAZATO M, MURAKAMI N, DATE Y et al.: A role for ghrelin in the central regulation of feeding. Nature (2001) 409:194-198.
79. WREN AM, SEAL LJ, COHEN MA et al.: Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. (2001) 86(12):5992.
80. SHUTO Y, SHIBASAKI T, OTAGIRI A et al.: Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J. Clin. Invest. (2002) 109(11):1429-1436.
81. TRAEBERT M, RIEDIGER T, WHITEBREAD S, SCHARRER E, SCHMID HA: Ghrelin acts on leptin-responsive neurones in the rat arcuate nucleus. J. Neuroendocrinol. (2002) 14(7):580-586.
82. MACNEIL DJ, HOWARD AD, GUAN X et al.: The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur. J. Pharmacol. (2002) 450(1):93-109. Excellent review of melanocortin signalling, the development of modulators of receptors for melanocortins and their potential role as antiobesity agents.
83. WIKBERG JE: Melanocortin receptors: perspectives for novel drugs. Eur. J. Pharmacol. (1999) 375(1-3):295-310.
84. BAGNOL D, LU XY, KAELIN CB et al.: Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J. Neurosci. (1999) 19(18):RC26.
85. MIZUNO TM, KLEOPOULOS SP, BERGEN HT, ROBERTS JL, PRIEST CA, MOBBS CV: Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin. Diabetes (1998) 47(2):294-297.
86. XIA Y, WIKBERG JE: Localization of ACTH receptor mRNA by in situ hybridization in mouse adrenal gland. Cell Tissue Res. (1996) 286(1):63-68.
87. BOSTON BA, CONE RD: Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Endocrinology (1996) 137(5):2043-2050.
88. ROSELLI-REHFUSS L, MOUNTJOY KG, ROBBINS LS et al.: Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc. Natl. Acad. Sci USA (1993) 90(19):8856-8860.
89. JEGOU S, BOUTELET I, VAUDRY H: Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. J. Neuroendocrinol. (2000) 12(6):501-505.
90. MOUNTJOY KG, MORTRUD MT, LOW MJ, SIMERLY RB, CONE RD: Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. (1994) 8(10):1298-1308.
91. COWLEY MA, PRONCHUK N, FAN W, DINULESCU DM, COLMERS WF, CONE RD: Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventriculas nucleus: evidence of a cellular basis for the adipostat. Neuron (1999) 24(1):155-163.
92. FONG TM, MAO C, MACNEIL T et al.: ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem. Biophys. Res. Commun. (1997) 237(3):629-631.
93. NIJENHUIS WA, OOSTEROM J, ADAN RA: AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. (2001) 15(1):164-171.
94. FEKETE C, LEGRADI G, MIHALY E et al.: Alpha-melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventriculas nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J. Neurosci. (2000) 20(4):1550-1558.
95. LEGRADI G, LECHAN RM: Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology (1999) 140(8):3643-3652.
96. BROBERGER C: Hypothalamic cocaine-and amphetamine-regulated transcript (CART) neurons: histochemical relationship to thyrotropin-releasing hormone, melanin-concentrating hormone, orexin/hypocretin and neuropeptide Y. Brain Res. (1999) 848(1-2):101-113.
97. CSIFFARY A, GORCS TJ, PALKOVITS M: Neuropeptide Y innervation of ACTH-immunoreactive neurons in the arcuate nucleus of rats: a correlated light and electron microscopic double immunolabeling study. Brain Res. (1990) 506(2):215-222.
98. HAGAN MM, BENOIT SC, RUSHING PA, PRITCHARD LM, WOODS SC, SEELEY RJ: Immediate and prolonged patterns of Agouti-related peptide-(83 - 132)-induced c-Fos activation in hypothalamic and extrahypothalamic sites. Endocrinology (2001) 142(3):1050-1056.
99. MARSH DJ, HOLLOPETER G, HUSZAR D et al.: Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat. Genet. (1999) 21(1):119-122.
100. YASWEN L, DIEHL N, BRENNAN MB, HOCHGESCHWENDER U: Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat. Med. (1999) 5(9):1066-1070.
101. CHEN AS, MARSH DJ, TRUMBAUER ME et al.: Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. (2000) 26(1):97-102.
102. BUTLER AA, KESTERSON RA, KHONG K et al.: A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology (2000) 141(9):3518-3521.
103. BUTLER AA, MARKS DL, FAN W, KUHN CM, BARTOLOME M, CONE RD: Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat. Neurosci. (2001) 4(6):605-611.
104. CHEN AS, METZGER JM, TRUMBAUER ME et al.: Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res. (2000) 9(2):145-154.
105. HUSZAR D, LYNCH CA, FAIRCHILD-HUNTRESS V et al.: Targeted disruption of the melanocotrin-4 receptor results in obesity in mice. Cell (1997) 88(1):131-141. Excellent paper indicating the importance of MC4 receptors in maintaining energy homeostasis and their potential as targets for antiobesity strategies.
106. STE MARIE L, MIURA GI, MARSH DJ, YAGALOFF K, PALMITER RD: A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc. Natl. Acad. Sci. USA (2000) 97(22):12339-12344.
107. FAN W, DINULESCU DM, BUTLER AA, ZHOU J, MARKS DL, CONE RD: The central melanocortin system can directly regulate serum insulin levels. Endocrinology (2000) 141(9):3072-3079.
108. OBICI S, FENG Z, TAN J, LIU L, KARKANIAS G, ROSSETTI L: Central melanocortin receptors regulate insulin action. J. Clin. Invest. (2001) 108(7):1079-1085.
109. FAROOQI IS, YEO GS, KEOGH JM et al.: Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. (2000) 106(2):271-279.
110. GU W, TU Z, KLEYN PW et al.: Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes (1999) 48(3):635-639.
111. CHAGNON YC, CHEN WJ, PERUSSE L et al.: Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study. Mol. Med. (1997) 3(10):663-673.
112. SAWYER TK, SANFILIPPO PJ, HRUBY VJ et al.: 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. USA (1980) 77(10):5754-5758.
113. AL-OBEIDI F, CASTRUCCI AM, HADLEY ME, HRUBY VJ: Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J. Med. Chem. (1989) 32(12):2555-2561.
114. HRUBY VJ, LU D, SHARMA SD et al.: Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. (1995) 38(18):3454-3461.
115. FAN W, BOSTON BA, KESTERSON RA, HRUBY VJ, CONE RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 385:165-168.
116. GRLLL HJ, GINSBERG AB, SEELEY RJ, KAPLAN JM: Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J. Neurosci. (1998) 18(23):10128-10135.
117. BEDNAREK MA, MACNEIL T, KALYANI RN, TANG R, VAN DER PLOEG LH, WEINBERG DH: Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. J. Med. Chem. (2001) 44(22):3665-3672.
118. BEDNAREK MA, MACNEIL T, TANG R, KALYANI RN, VAN DER PLOEG LH, WEINBERG DH: Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem. Biophys. Res. Commun. (2001) 286(3):641-645.
119. BLUNDELL JE: Serotonin and appetite. Neuropharmacology (1984) 23:1537-1551.
120. LEIBOWITZ SF, WEISS GF, SHORPOSNER G: Hypothalamic serotonin: Pharmacological, biochemical and behavioral analyses of its feeding suppressive action. Clin. Neuropharmacol. (1988) 11:S51-S71.
121. CURZON G, GIBSON EL, OLOYOMI A: Appetite suppression by commonly used drugs depends on 5-HT receptors but not 5-HT availability. Trends Pharmacol. Sci. (1997) 18:21-25.
122. NONOGAKI K, STRACK AM, DALLMAN MF, TECOTT LH: Leptin independent hyperphagia and type 2 diabetes in ice with a mutated serotonin 5-HT2c receptor gene. Nature (1998) 4:1152-1156.
123. HIRANO T: Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. (1998) 16(3-4):249-284.
124. GLOAGUEN I, COSTA P, DEMARTIS A et al.: Ciliary neurotrophic factor cortects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl. Acad. Sci. USA (1997) 94(12):6456-6461.
125. LAMBERT PD, ANDERSON KD, SLEEMAN MW et al.: Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. USA (2001) 98(8):4652-4657. Excellent paper indicating the potential for CNTF and related compounds to mimic actions of leptin and highlight the potential for this signalling pathway for antiobesity strategies.
126. PU S, DHILLON H, MOLDAWER LL, KALRA PS, KALRA SP: Neuropeptide Y counteracts the anorectic and weight reducing effects of ciliary neurotropic factor. J. Neuroendocrinol. (2000) 12(9):827-832.
127. KALRA SP, XU B, DUBE MG, MOLDAWER LL, MARTIN D, KALRA PS: Leptin and ciliary neurotropic factor (CNTF) inhibit fasting-induced suppression of luteinizing hormone release in rats: role of neuropeptide Y. Neurosci. Lett. (1998) 240(1):45-49.
128. XU B, DUBE MG, KALRA PS et al.: Anorectic effects of the cytokine, ciliary neurotropic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. Endocrinology (1998) 139(2):466-473.
129. DAVIS S, ALDRICH TH, VALENZUELA DM et al.: The receptor for ciliary neurotrophic factor. Science (1991) 253:59-63.
130. KORDOWER JH, YAPING-CHU, MACLENNAN AJ: Ciliary neurotrophic factor receptor alpha-immunoreactivity in the monkey central nervous system. J. Comp. Neurol. (1997) 377(3):365-380.
131. BJORBAEK C, ELMQUIST JK, EL-HASCHIMI K et al.: Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor. Endocrinology (1999) 140(5):2035-2043.
132. BOUILLAUD F, RICQUIER D, THIBAULT J, WEISSENBACH J: Molecular approach to thermogenesis in brown adipose tissue: cDNA cloning of the mitochondrial uncoupling protein. Proc. Natl. Acad. Sci. USA (1985) 82(2):445-448.
133. KLINGENBERG M, HUANG SG: Structure and function of the uncoupling protein from brown adipose tissue. Biochim. Biophys. Acta (1999) 1415(2):271-296.
134. ARCH JR, WILSON S: Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int. J. Obes. Relat. Metab. Disord. (1996) 20(3):191-199.
135. HARPER JA, DICKINSON K, BRAND MD: Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes. Rev. (2001) 2(4):255-265. Excellent review of recent developments in our understanding of uncoupling proteins and the renewed interest in these proteins for antiobesity strategies.
136. WEYER C, GAUTIER JF, DANFORTH E JR: Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab. (1999) 25(1):11-21.
137. BOSS O, SAMEC S, PAOLONI-GIACOBINO A et al.: Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett. (1997) 408(1):39-42.
138. GONG DW, HE Y, KARAS M, REITMAN M: Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic agonists, and leptin. J. Biol. Chem. (1997) 272(39):24129-24132.
139. VIDAL-PUIG A, SOLANES G, GRUJIC D, FLIER JS, LOWELL BB: UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem. Biophys. Res. Commun. (1997) 235(1):79-82.
140. ZHANG CY, BAFFY G, PERRET P et al.: Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell (2001) 105(6):745-755.
141. PAULIK MA, BUCKHOLZ RG, LANCASTER ME et al.: Development of infrared imaging to measure thermogenesis in cell culture: thermogenic effects of uncoupling protein-2, troglitazone, and beta-adrenoceptor agonists. Pharm. Res. (1998) 15(6):944-949.
142. COLOMBO G, AGABIO R, DIAZ G, LOBINA C, REALI R, GESSA GL: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. (1998) 63(8):PL113-PL117.
143. WILLIAMS CM, KIRKHAM TC: Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl). (1999) 143(3):315-317.
144. RAVINET-TRILLOU C, ARNONE M, DELGORGE C et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284(2):R345-R353.
145. MAILLEUX P, VANDERHAEGHEN JJ: Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience (1992) 48(3):655-668.
146. JAMSHIDI N, TAYLOR DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. (2001) 134(6):1151-1154.
147. DI MARZO V, GOPARAJU SK, WANG L et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410:822-825. Important paper highlighting the role of central cannabinoid receptors in feeding and leptin-sensitive pathways.
148. ADAMS LD, GONG W, VECHIA SD, HUNTER RG, KUHAR MJ: CART: from gene to function. Brain Res. (1999) 848(1-2):137-140. Excellent review of CART peptides.
149. BANNON AW, SEDA J, CARMOUCHE M, FRANCIS JM, JAROSINSKI MA, DOUGLASS J: Multiple behavioral effects of cocaine- and amphetamine-regulated transcript (CART) peptides in mice: CART 42-89 and CART 49-89 differ in potency and activity. J. Pharmacol. Exp. Ther. (2001) 299(3):1021-1026.
150. LAMBERT PD, COUCEYRO PR, MCGIRR KM, DALL VECHIA SE, SMITH Y, KUHAR MJ: CART peptides in the central control of feeding and interactions with neuropeptide Y. Synapse (1998) 29(4):293-298.
151. AJA S, SAHAND YS, LADENHEIM EE, SCHWARTZ GJ, MORAN TH: Intracerebroventricular CART peptide reduces food intake and alters motor behavior at a hindbrain site. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281(6):R1862-R1867.
152. ZHENG H, PATTERSON C, BERTHOUD HR: Fourth ventricular injection of CART peptide inhibits short-term sucrose intake in rats. Brain Res. (2001) 896(1-2):153-156.
153. ABBOTT CR, ROSSI M, WREN AM et al.: Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. Endocrinology (2001) 142(8):3457-3463.
154. ASNICAR MA, SMITH DP, YANG DD et al.: Absence of cocaine- and amphetamine-regulated transcript results in obesity in mice fed a high caloric diet. Endocrinology (2001) 142(10):4394-4400.
155. VRANG N, LARSEN PJ, CLAUSEN JT, KRISTENSEN P: Neurochemical characterization of hypothalamic cocaine-amphetamine-regulated transcript neurons. J. Neurosci (1999) 19(10):RC5.
156. ROBSON AJ, ROUSSEAU K, LOUDON AS, EBLING FJ: Cocaine and amphetamine-regulated transcript mRNA regulation in the hypothalamus in lean and obese rodents. J. Neuroendocrinol. (2002) 14(9):697-709.
157. DEL GIUDICE EM, SANTORO N, CIRILLO G, D'URSO L, DI TORO R, PERRONE L: Mutational screening of the CART gene in obese children: identifying a mutation (Leu34Phe) associated with reduced resting energy expenditure and cosegregating with obesity phenotype in a large family. Diabetes (2001) 50(9):2157-2160.
158. BANNON AW, SEDA J, CARMOUCHE M, FRANCIS JM, JAROSINSKI MA, DOUGLASS J: Multiple behavioral effects of cocaine- and amphetamine-regulated transcript (CART) peptides in mice: CART 42-89 and CART 49-89 differ in potency and activity. J. Pharmacol. Exp. Ther. (2001) 299(3):1021-1026.